In a significant development for global health, Serum Institute of India Pvt. Ltd. Has announced a ground-breaking licensing agreement with the University of Oxford to manufacture and distribute a chimeric protein-based vaccine targeting Meningitis-B. This collaboration, spanning five years, aims to combat a severe infection that poses risks to the brain and spinal cord.

Serum Institute’s Commitment to Global Health: Adar Poonawalla, CEO of Serum Institute, emphasized the importance of accessible vaccines in the fight against diseases and expressed commitment to global health. He highlighted the partnership as a shared dedication to improving health outcomes worldwide, especially in regions vulnerable to meningitis outbreaks.

“This collaboration exemplifies a shared dedication to global health and underscores the importance of accessible vaccines,” said Adar Poonawalla. “Our goal is to ensure life-saving protection reaches those who need it most.”

Milestone for Vaccine Innovation: The licensing agreement with Oxford University marks a significant milestone in vaccine innovation. Simon Warner, Head of Licensing & Ventures – Life Sciences at Oxford University Innovation, praised the agreement as a testament to Oxford’s commitment to developing effective vaccines.

“The Men-B vaccine agreement with the Serum Institute of India is another example of vaccine innovation at the University of Oxford,” said Simon Warner. “Oxford’s investment in developing deployable vaccines will protect millions of lives, and academic licensing and successful commercial partnerships play a crucial role in addressing global health challenges.”

Serum Institute’s Role in Combating Meningitis: Serum Institute’s collaboration with Oxford University builds on its success with the MenFive vaccine, which received pre-qualification from the World Health Organization in July 2023. This achievement solidified Serum Institute’s role as a key player in combating meningitis outbreaks on a global scale.
The partnership between Serum Institute and Oxford University reflects a shared commitment to advancing vaccine research and accessibility. By utilising academic expertise and industry experience, the collaboration aims to develop and distribute life-saving vaccines to populations in need. As Serum Institute continues to expand its portfolio of vaccines, including efforts to combat meningitis, the company reaffirms its dedication to improving global health outcomes and addressing pressing public health challenges.

The licensing agreement between Serum Institute of India and Oxford University represents a significant step forward in the fight against Meningitis-B. By combining scientific expertise and resources, the collaboration aims to develop and distribute an effective vaccine that will protect vulnerable populations worldwide. This partnership showcases the importance of innovation and collaboration in addressing global health challenges and improving access to life-saving vaccines.